Grundläggande statistik
| LEI | 5493002WIJCSC2L2VL79 |
| CIK | 906338 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Taro Pharmaceutical Industries Ltd.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35463 Taro Pharmaceutical Industries Ltd. (Exact name of registrant as |
|
| June 24, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on July 05, 2024, pursuant to the provisions of Rule 12d2-2 (a). |
|
| June 24, 2024 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 7) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation S |
|
| June 24, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| June 24, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 31) Under the Securities Exchange Act of 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Issuer) ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE (Title of Class of Securities) M8737E108 (CUSIP Number) Mr. Sailesh T Desai c/o Sun Pharmaceutical Industries Ltd. Sun House, Plot No. 201 B/1 |
|
| June 24, 2024 |
EX-99.60 Exhibit 99.60 Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: [email protected] CIN: L24230GJ1993PLC019050 FOR IMMEDIATE RELEASE Sun Pharma Completes Taro Merger Combined entity is better positioned to compete in increasing |
|
| June 24, 2024 |
EX-99.1 Exhibit 99.1 Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: [email protected] CIN: L24230GJ1993PLC019050 FOR IMMEDIATE RELEASE Sun Pharma Completes Taro Merger Combined entity is better positioned to compete in increasingly |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 6) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 23, 2024 |
Taro Shareholders Approve Merger with Sun Pharma Taro Shareholders Approve Merger with Sun Pharma Mumbai, India and New York, USA May 23, 2024 – Sun Pharmaceutical Industries Limited (Reuters: SUN. |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 5) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma |
|
| May 8, 2024 |
Exhibit (a)(3)(vi) Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger New York, USA May 8, 2024 – Taro Pharmaceutical Industries Ltd. |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 4) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma |
|
| April 15, 2024 |
TARO PHARMACEUTICAL INDUSTRIES LTD. (the “Company”) EX-99.(a)(3)(v) Exhibit (a)(3)(v) TARO PHARMACEUTICAL INDUSTRIES LTD. (the “Company”) In accordance with Section 318(b) of the Israeli Companies Law, 1999, and Regulation 3 of the Israeli Companies Regulations (Merger), 2000, this notice is hereby given to the Company’s creditors, if any, that the Company submitted to the Companies Registrar on April 15, 2024, a merger proposal for the merger of L |
|
| April 15, 2024 |
EX-99.(a)(3)(iv) Exhibit (a)(3)(iv) Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd. New York, USA April 15, 2024 – Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced that it has called an extraordinary general meeting of its shareholders (the “Extraordinary |
|
| April 15, 2024 |
SC 13E3/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 3) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation S |
|
| April 15, 2024 |
EX-99.(a)(3)(i) Table of Contents Exhibit (a)(3)(i) PROXY STATEMENT TARO PHARMACEUTICAL INDUSTRIES LTD. 14 Hakitor Street Haifa Bay 2624761, Israel Telephone: +972 4 8475600 Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of the shareholders (which we refer to as the “extraordinary general meeting”) of Taro Pharmaceutical Industries Ltd. (which we refer to as |
|
| March 20, 2024 |
Table of Contents Exhibit (a)(3)(i) **PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION** TARO PHARMACEUTICAL INDUSTRIES LTD. |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 2) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma |
|
| March 20, 2024 |
ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www. |
|
| March 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) Taro Pharmaceutical Industries Ltd. |
|
| March 11, 2024 |
ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP ONE MANHATTAN WEST NEW YORK, NY 10001 TEL: (212) 735-3000 FAX: (212) 735-2000 www. |
|
| March 11, 2024 |
Table of Contents Exhibit (a)(3)(i) **PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION** TARO PHARMACEUTICAL INDUSTRIES LTD. |
|
| March 11, 2024 |
Project Turtle Shareholder Base Overview November 2023 Exhibit (c)(4) Project Turtle Shareholder Base Overview November 2023 Notice to Recipient Confidential “Bank of America” and “BofA Securities” are the marketing names used by the Global Banking and Global Markets divisions of Bank of America Corporation. |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Amendment No. 1) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma |
|
| February 15, 2024 |
Exhibit (c)(5) Project TurtleDecember 2023 Notice to RecipientConfidentialThese materials have been prepared by one or more affiliates of Bank of America Corporation for the client or potential client to whom such materials are directly addressed and delivered (the “Company”) for discussion purposes only in connection with an actual or potential mandate or engagement and are subject to our review and assessment from a legal, compliance, accounting policy and risk perspective, as appropriate. |
|
| February 15, 2024 |
Table of Contents Exhibit (a)(3)(i) **PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION** TARO PHARMACEUTICAL INDUSTRIES LTD. |
|
| February 15, 2024 |
Turtle Litigation & Settlements OverviewDecember 2023 Exhibit (c)(4) Turtle Litigation & Settlements OverviewDecember 2023 Notice to RecipientConfidentialThese materials have been prepared by one or more affiliates of Bank of America Corporation for the client or potential client to whom such materials are directly addressed and delivered (the “Company”) for discussion purposes only in connection with an actual or potential mandate or engagement and are subject to our review and assessment from a legal, compliance, accounting policy and risk perspective, as appropriate. |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 Taro Pharmaceutical Industries Ltd. (Name of the Issuer) Taro Pharmaceutical Industries Ltd. Sun Pharmaceutical Industries Ltd. Alkaloida Chemical Company ZRT The Taro Development Corporation Sun Pharma Holdings Libra Mer |
|
| February 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 13E-3 (Form Type) Taro Pharmaceutical Industries Ltd. |
|
| February 15, 2024 |
Confidential Project Turtle Presentation to the Special Committee January 17, 2024 Exhibit (c)(6) Confidential Project Turtle Presentation to the Special Committee January 17, 2024 Notice to Recipient Confidential These materials have been prepared by one or more subsidiaries of Bank of America Corporation for the Special Committee of the Board of Directors (the “Committee”) of Taro Pharmaceutical Industries Ltd. |
|
| February 15, 2024 |
Project Turtle Presentation to the Special Committee October 23, 2023 Exhibit (c)(2) Project Turtle Presentation to the Special Committee October 23, 2023 Notice to Recipient Confidential “Bank of America” and “BofA Securities” are the marketing names used by the Global Banking and Global Markets divisions of Bank of America Corporation. |
|
| February 15, 2024 |
Project Turtle Follow-Up Supporting Materials October 27, 2023 Exhibit (c)(3) Project Turtle Follow-Up Supporting Materials October 27, 2023 Notice to Recipient Confidential “Bank of America” and “BofA Securities” are the marketing names used by the Global Banking and Global Markets divisions of Bank of America Corporation. |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| January 17, 2024 |
EX-99.58 2 dp205320ex9958.htm EXHIBIT 99.58 Exhibit 99.58 EXECUTION VERSION AGREEMENT OF MERGER This Agreement of Merger is made and entered into as of January 17, 2024 by and among Sun Pharmaceutical Industries Ltd., a corporation organized under the laws of India (“Parent”), Alkaloida Chemical Company ZRT (f/k/a Alkaloida Chemical Company Exclusive Group Limited) (“Alkaloida”), a corporation org |
|
| January 17, 2024 |
Exhibit 99.1 Taro Announces Merger Agreement with Sun Pharma Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 Mumbai, India and New York, USA January 17, 2024 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as “Sun Pharma”) and Taro Phar |
|
| January 17, 2024 |
Exhibit 99.2 EXECUTION VERSION AGREEMENT OF MERGER This Agreement of Merger is made and entered into as of January 17, 2024 by and among Sun Pharmaceutical Industries Ltd., a corporation organized under the laws of India (“Parent”), Alkaloida Chemical Company ZRT (f/k/a Alkaloida Chemical Company Exclusive Group Limited) (“Alkaloida”), a corporation organized under the laws of Hungary and under th |
|
| January 17, 2024 |
SC 13D/A 1 dp205320sc13da-30.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 30) Under the Securities Exchange Act of 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Issuer) ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE (Title of Class of Securities) M8737E108 (CUSIP Number) Mr. Sailesh T Desai c/o Sun Pharmaceutical Indus |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of Registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of Princi |
|
| January 17, 2024 |
EX-99.59 3 dp205320ex9959.htm EXHIBIT 99.59 Exhibit 99.59 Taro Announces Merger Agreement with Sun Pharma Agreed Price of US$43.00 per Share to Deliver 48% Premium to Unaffected Price on May 25, 2023 Mumbai, India and New York, USA January 17, 2024 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or assoc |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 29) Under the Securities Exchange Act of 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Issuer) ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE (Title of Class of Securities) M8737E108 (CUSIP Number) Mr. Sailesh T Desai c/o Sun Pharmaceutical Industries Ltd. Sun House, Plot No. 201 B/1 Western |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of Registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of Princ |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| June 29, 2023 |
Exhibit 2.2 Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Registered Under Section 12 of the Exchange Act As of March 31, 2023, Taro Pharmaceuticals Industries Ltd. (hereinafter, “we,” “us,” “our,” “our company” or similar expressions) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 – ordinary shares, NIS 0.0001 par value per s |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 29, 2023 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 29, 2023 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Uday Baldota, Chief Executive Officer an |
|
| June 29, 2023 |
Exhibit 12.2 CERTIFICATION I, William Coote, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of Registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of Principal |
|
| May 26, 2023 |
Strictly Private and Confidential Exhibit 99.57 Strictly Private and Confidential Non-Binding Board of Directors Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay 2624761 Israel May 26, 2023 Re: Indicative Non-binding Proposal (the “Proposal”) Dear Members of the Board of Directors, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”), by itself or by any affiliated entity (“Purchaser”), is pleased to present this Propo |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of Registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of Principal |
|
| May 26, 2023 |
Strictly Private and Confidential Exhibit 99.1 Strictly Private and Confidential Non-Binding Board of Directors Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay 2624761 Israel May 26, 2023 Re: Indicative Non-binding Proposal (the “Proposal”) Dear Members of the Board of Directors, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”), by itself or by any affiliated entity (“Purchaser”), is pleased to present this Propos |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 28) Under the Securities Exchange Act of 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Issuer) ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE (Title of Class of Securities) M8737E108 (CUSIP Number) Mr. Sailesh T Desai c/o Sun Pharmaceutical Industries Ltd. Sun House, Plot No. 201 B/1 Western |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| March 27, 2023 |
6-K 1 ss19092236k.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princip |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 18, 2022 |
6-K 1 taro-6-k2022proxy.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2 |
|
| November 9, 2022 |
6-K 1 d411247d6k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761 |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 27) Under the Securities Exchange Act of 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Issuer) ORDINARY SHARES, PAR VALUE NIS 0.0001 PER SHARE (Title of Class of Securities) M8737E108 (CUSIP Number) Mr. Sailesh T Desai c/o Sun Pharmaceutical Industries Ltd. Sun House, Plot No. 201 B/1 Western |
|
| September 8, 2022 |
Fourth Joinder Agreement Dated as of September 8, 2022 Fourth Joinder Agreement Dated as of September 8, 2022 The undersigned hereby agrees to join as a party to that certain Agreement of Joint Filing, dated as of July 2, 2007, as amended, among Sun Pharmaceutical Industries Ltd. |
|
| September 8, 2022 |
Fifth Joinder Agreement Dated as of September 8, 2022 Fifth Joinder Agreement Dated as of September 8, 2022 The undersigned hereby agrees to join as a party to that certain Agreement of Joint Filing, dated as of July 2, 2007, as amended, among Sun Pharmaceutical Industries Ltd. |
|
| September 8, 2022 |
Sixth Joinder Agreement Dated as of September 8, 2022 Sixth Joinder Agreement Dated as of September 8, 2022 The undersigned hereby agrees to join as a party to that certain Agreement of Joint Filing, dated as of July 2, 2007, as amended, among Sun Pharmaceutical Industries Ltd. |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| July 25, 2022 |
Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Exhibit 2.2 Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Registered Under Section 12 of the Exchange Act As of March 31, 2022, Taro Pharmaceuticals Industries Ltd. (hereinafter, ?we,? ?us,? ?our,? ?our company? or similar expressions) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 ? ordinary shares, NIS 0.0001 par value per s |
|
| July 25, 2022 |
Compensation Policy for Office Holders Exhibit 4.4 Taro Pharmaceutical Industries Ltd. Compensation Policy for Office Holders (effective December 14, 2020) 1. Introduction and Establishment 1.1 Taro Pharmaceutical Industries Ltd. (hereinafter: ?Taro? or the ?Company?) is a multinational, science-based pharmaceutical company, operating primarily in the United States, Canada and Israel, through three entities: (i) Taro Israel, and two of |
|
| July 25, 2022 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the ?Company?) on Form 20-F for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), we, Uday Baldota, Chief Executive Officer an |
|
| July 25, 2022 |
Indemnification Agreement Template Exhibit 4.5 indemnification agreement THIS INDEMNIFICATION AGREEMENT (the ?Agreement?), dated as of January 1, 2018, is entered into by and between Taro Pharmaceutical Industries Ltd., an Israeli company whose address is 14 Hakitor St., Haifa Bay 26110, Israel (the ?Company?), and , a of the Company whose address is (the ?Indemnitee?). WHEREAS, Indemnitee is an Office Holder (?Nosse Misra?), as su |
|
| July 25, 2022 |
Exhibit 12.2 CERTIFICATION I, William Coote, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| July 25, 2022 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 27, 2022 |
6-K 1 taro-6k-earningsye.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624 |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 17, 2021 |
Exhibit 12.2 CERTIFICATION I, Daphne Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 17, 2021 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the ?Company?) on Form 20-F for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), we, Uday Baldota, Chief Executive Officer an |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 17, 2021 |
Exhibit 2.2 Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Registered Under Section 12 of the Exchange Act As of March 31, 2021, Taro Pharmaceuticals Industries Ltd. (hereinafter, ?we,? ?us,? ?our,? ?our company? or similar expressions) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 ? ordinary shares, NIS 0.0001 par value per s |
|
| June 17, 2021 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| January 28, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2021 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 21, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 4, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| October 28, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| July 30, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| July 23, 2020 |
Current Report of Foreign Issuer - 6-K - DOJ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 19, 2020 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Uday Baldota, Chief Executive Officer an |
|
| June 19, 2020 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 19, 2020 |
Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Exhibit 2.2 Description of Taro Pharmaceutical Industries Ltd. Ordinary Shares Registered Under Section 12 of the Exchange Act As of March 31, 2020, Taro Pharmaceuticals Industries Ltd. (hereinafter, “we,” “us,” “our,” “our company” or similar expressions) had one class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 – ordinary shares, NIS 0.0001 par value per s |
|
| June 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 19, 2020 |
Exhibit 12.2 CERTIFICATION I, Daphne Huang, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 20, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 15, 2020 |
May 15, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 10, 2020 |
April 10, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 6, 2020 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princip |
|
| February 21, 2020 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| February 20, 2020 |
February 20, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 7, 2020 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| February 4, 2020 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| January 10, 2020 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| December 23, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| December 23, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K - EGM UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| December 20, 2019 |
TARO ANNOUNCES FINAL RESULTS OF ITS TENDER OFFER EX-99.(a)(1)(J) Exhibit (a)(1)(J) Taro Pharmaceutical Industries Ltd. c/o Taro Pharmaceuticals U.S.A., Inc. Three Skyline Drive Hawthorne, New York 10532 (NYSE: TARO) FOR IMMEDIATE RELEASE CONTACT: William J. Coote VP, Treasurer (914) 345-9001 [email protected] TARO ANNOUNCES FINAL RESULTS OF ITS TENDER OFFER Hawthorne, NY, December 19, 2019 – Taro Pharmaceutical Industries Ltd. (NYSE: TARO) |
|
| December 20, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. SC TO-I/A - - SC TO-I/A SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Subject Company (Issuer)) TARO PHARMACEUTICAL INDUSTRIES LTD. (ISSUER) (Names of Filing Persons (Issuer and Offeror)) ORDINARY SHARES, NOMINAL (PAR) VALUE NIS 0 |
|
| December 17, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. SC TO-I/A - - SC TO-I/A SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Subject Company (Issuer)) TARO PHARMACEUTICAL INDUSTRIES LTD. (ISSUER) (Names of Filing Persons (Issuer and Offeror)) ORDINARY SHARES, NOMINAL (PAR) VALUE NIS 0 |
|
| December 17, 2019 |
TARO ANNOUNCES PRELIMINARY RESULTS OF ITS TENDER OFFER EX-99.(a)(1)(I) Exhibit (a)(1)(I) Taro Pharmaceutical Industries Ltd. c/o Taro Pharmaceuticals U.S.A., Inc. Three Skyline Drive Hawthorne, New York 10532 (NYSE: TARO) FOR IMMEDIATE RELEASE CONTACT: William J. Coote AVP, Treasurer (914) 345-9001 [email protected] TARO ANNOUNCES PRELIMINARY RESULTS OF ITS TENDER OFFER Hawthorne, NY, December 17, 2019 – Taro Pharmaceutical Industries Ltd. (NYSE: |
|
| December 17, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay, 2624761, Israel (Address of |
|
| December 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| December 3, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. CORRESP - - CORRESP 599 LEXINGTON AVENUE NEW YORK, NY 10022-6069 +1.212.848.4000 December 3, 2019 VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Joshua Shainess Re: Taro Pharmaceutical Industries Ltd. Schedule TO-I Filed November 15, 2019 File No. 005-49231 Dear Mr. Shainess: On behalf of our client, |
|
| December 3, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. SC TO-I/A - - SC TO-I/A SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Subject Company (Issuer)) TARO PHARMACEUTICAL INDUSTRIES LTD. (ISSUER) (Names of Filing Persons (Issuer and Offeror)) ORDINARY SHARES, NOMINAL (PAR) VALUE NIS 0 |
|
| November 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 15, 2019 |
DECLARATION OF STATUS FOR ISRAELI INCOME TAX PURPOSES EX-99.(a)(1)(F) Exhibit (a)(1)(F) DECLARATION OF STATUS FOR ISRAELI INCOME TAX PURPOSES You are receiving this form “Declaration of Status For Israeli Income Tax Purposes” as a holder of ordinary shares, nominal (par) value NIS 0.0001 per share (the “Shares”) of Taro Pharmaceutical Industries Ltd. (“Taro”), in connection with Taro’s commencement of a modified “Dutch auction” tender offer to repurc |
|
| November 15, 2019 |
EX-99.(A)(1)(E) Exhibit (a)(1)(E) OFFER TO PURCHASE FOR CASH BY TARO PHARMACEUTICAL INDUSTRIES LTD. OF UP TO $225 MILLION IN VALUE OF SHARES OF ITS ORDINARY SHARES AT A PURCHASE PRICE NOT GREATER THAN $92.00 PER SHARE NOR LESS THAN $80.00 PER SHARE THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MONDAY, DECEMBER 16, 2019, UNLESS THE OFFER IS EXTEN |
|
| November 15, 2019 |
EX-99.(a)(1)(G) Exhibit (a)(1)(G) Contacts: Mariano A. Balaguer William J. Coote VP, CFO VP, Treasurer (914) 345-9001 (914) 345-9001 [email protected] [email protected] TARO ANNOUNCES COMMENCEMENT OF TENDER OFFER TO REPURCHASE UP TO $225 MILLION IN VALUE OF ITS ORDINARY SHARES HAWTHORNE, NY, November 15, 2019—Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) a |
|
| November 15, 2019 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) OFFER TO PURCHASE FOR CASH BY TARO PHARMACEUTICAL INDUSTRIES LTD. OF UP TO $225 MILLION IN VALUE OF SHARES OF ITS ORDINARY SHARES AT A PURCHASE PRICE NOT GREATER THAN $92.00 PER SHARE NOR LESS THAN $80.00 PER SHARE THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MONDAY, DECEMBER 16, 2019, UNLESS THE OFFER IS EXTEN |
|
| November 15, 2019 |
EX-99.(a)(1)(H) Exhibit (a)(1)(H) This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares. The Offer (as defined below) is made solely by the Offer to Purchase, dated November 15, 2019, and the related Letter of Transmittal, and any amendments or supplements thereto. The Offer is not being made to, nor will tenders be accepted from or on behalf of, holders o |
|
| November 15, 2019 |
EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY (Not to be used for Signature Guarantee) for Tender of Ordinary Shares of TARO PHARMACEUTICAL INDUSTRIES LTD. THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MONDAY, DECEMBER 16, 2019, UNLESS THE OFFER IS EXTENDED. As set forth in Section 3 of the Offer to Purchase (as defined below) |
|
| November 15, 2019 |
EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH BY TARO PHARMACEUTICAL INDUSTRIES LTD. OF UP TO $225 MILLION IN VALUE OF ITS ORDINARY SHARES AT A PURCHASE PRICE NOT GREATER THAN $92.00 PER SHARE NOR LESS THAN $80.00 PER SHARE THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON MONDAY, DECEMBER 16, 2019, UNLESS THE OFFER |
|
| November 15, 2019 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL TO TENDER ORDINARY SHARES PURSUANT TO THE OFFER TO PURCHASE DATED NOVEMBER 15, 2019 by TARO PHARMACEUTICAL INDUSTRIES LTD. of UP TO $225 MILLION IN VALUE OF SHARES OF ITS ORDINARY SHARES AT A PURCHASE PRICE NOT GREATER THAN $92.00 PER SHARE NOR LESS THAN $80.00 PER SHARE THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P. |
|
| November 15, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. SC TO-I - - SC TO-I SC TO-I SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TARO PHARMACEUTICAL INDUSTRIES LTD. (Name of Subject Company (Issuer)) TARO PHARMACEUTICAL INDUSTRIES LTD. (ISSUER) (Names of Filing Persons (Issuer and Offeror)) ORDINARY SHARES, NOMINAL (PAR) VALUE NIS 0.0001 PER SHARE (Tit |
|
| November 6, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. 6-K - Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| August 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| June 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 20, 2019 |
Exhibit 12.2 CERTIFICATION I, Mariano Balaguer, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| June 20, 2019 |
TARO / Taro Pharmaceutical Industries, Ltd. 20-F - - 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 20, 2019 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Uday Baldota, Chief Executive Officer an |
|
| June 20, 2019 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| January 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| January 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2019 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| October 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| September 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of pri |
|
| August 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| August 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| June 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 21, 2018 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Uday Baldota, Chief Executive Officer an |
|
| June 21, 2018 |
Exhibit 12.1 CERTIFICATION I, Uday Baldota, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 21, 2018 |
TARO / Taro Pharmaceutical Industries, Ltd. 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 21, 2018 |
Exhibit 12.2 CERTIFICATION I, Mariano Balaguer, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| May 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| February 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| January 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| January 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| November 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| November 22, 2017 |
TARO PHARMACEUTICAL INDUSTRIES LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 TARO PHARMACEUTICAL INDUSTRIES LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS November 22, 2017 Notice is hereby given that the annual general meeting of shareholders (the ? Annual General Meeting? or the ? Meeting?) of Taro Pharmaceutical Industries Ltd. (the ? Company?) will be held on December 28, 2017, at 10:00 a.m. (Israel time), at the offices of Meitar Liquornik Geva Les |
|
| November 22, 2017 |
Exhibit 99.2 TARO PHARMACEUTICAL INDUSTRIES LTD. Proxy for Annual General Meeting of Shareholders to be held on December 28, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of Taro Pharmaceutical Industries Ltd. (the ? Company ?) hereby appoints each of Myla Kaplan, Anat Edrey and Avi Avramoff, each with full power of substitution and each of them, the |
|
| November 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| October 30, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| September 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of p |
|
| September 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of pri |
|
| August 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| June 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 21, 2017 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the ?Company?) on Form 20-F for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), we, Abhay Gandhi, Interim Chief Executive Of |
|
| June 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 21, 2017 |
Exhibit 12.2 CERTIFICATION I, Mariano Balaguer, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mislead |
|
| June 21, 2017 |
Exhibit 12.1 CERTIFICATION I, Abhay Gandhi, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 22, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| February 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| January 31, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| January 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2017 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| December 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| December 1, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| November 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| November 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| November 23, 2016 |
Exhibit 99.2 TARO PHARMACEUTICAL INDUSTRIES LTD. Proxy for Annual General Meeting of Shareholders on December 29, 2016 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned shareholder of Taro Pharmaceutical Industries Ltd. (the ? Company?) hereby appoints each of Myla Kaplan, Anat Edrey and Avi Avramoff, each with full power of substitution and each of them, the true and law |
|
| November 23, 2016 |
TARO PHARMACEUTICAL INDUSTRIES LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 TARO PHARMACEUTICAL INDUSTRIES LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS November 22, 2016 Notice is hereby given that the annual general meeting of shareholders (the ? Annual General Meeting? or the ? Meeting?) of Taro Pharmaceutical Industries Ltd. (the ? Company?) will be held on December 29, 2016, at 10:00 a.m. (Israel time), at the offices of Meitar Liquornik Geva Les |
|
| November 23, 2016 |
TARO ANNOUNCES APPOINTMENT OF NEW CEO AND NEW BOARD MEMBER NOMINATIONS EX-99.3 4 a51465182ex993.htm EXHIBIT 99.3 Exhibit 99.3 Taro Pharmaceutical Industries Ltd. c/o Taro Pharmaceuticals U.S.A., Inc. Three Skyline Drive Hawthorne, New York 10532 (NYSE: TARO) FOR IMMEDIATE RELEASE CONTACTS: Mariano Balaguer William J. Coote VP, Chief Financial Officer (914) 345-9001 (914) 345-9001 [email protected] [email protected] TARO ANNOUNCES APPOINTMENT OF NEW CEO A |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| October 31, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| October 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princ |
|
| September 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of pri |
|
| August 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| August 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| August 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| July 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 21, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| June 9, 2016 |
Exhibit 12.2 CERTIFICATION I, Michael Kalb, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| June 9, 2016 |
EX-13 4 taro-ex13255.htm EX-13 Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kal Sunda |
|
| June 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR R ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN |
|
| June 9, 2016 |
Exhibit 12.1 CERTIFICATION I, Kal Sundaram, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| May 26, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| May 2, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal |
|
| March 15, 2016 |
a51301398.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Addr |
|
| February 10, 2016 |
a51276660.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (A |
|
| February 3, 2016 |
a51271767.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel |
|
| February 2, 2016 |
a51271767.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2016 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (A |
|
| December 28, 2015 |
a51250078.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (A |
|
| November 24, 2015 |
TARO PHARMACEUTICAL INDUSTRIES LTD. a51230775ex991.htm Exhibit 99.1 TARO PHARMACEUTICAL INDUSTRIES LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS November 16, 2015 Notice is hereby given that the annual general meeting of shareholders (the ?Annual General Meeting? or the ?Meeting?) of Taro Pharmaceutical Industries Ltd. (the ?Company?) will be held on December 24, 2015, at 10:00 a.m. (Israel time), at the offices of Meitar Li |
|
| November 24, 2015 |
a51230775.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel |
|
| November 24, 2015 |
a51230775ex992.htm Exhibit 99.2 |
|
| November 17, 2015 |
a51226023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (A |
|
| November 4, 2015 |
a51216356.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (A |
|
| October 27, 2015 |
a51210603.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Ad |
|
| September 21, 2015 |
a51185228.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel ( |
|
| August 10, 2015 |
a51159496.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Add |
|
| August 6, 2015 |
a51158622.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Add |
|
| July 30, 2015 |
a51153554.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Addre |
|
| July 28, 2015 |
Taro Pharmaceutical Industries ESP Response Letter Taro Pharmaceutical Industries Ltd. July 28, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Taro Pharmaceutical Industries Ltd. Form 20-F for the Fiscal Year Ended March 31, 2015 Filed July 1, 2015 File No. 001-35463 Dear Mr. Rosenberg: On behalf of Taro Pharmaceutical Industries Ltd. ( |
|
| July 1, 2015 |
Exhibit 12.2 CERTIFICATION I, Michael Kalb, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading |
|
| July 1, 2015 |
EX-12.1 Exhibit 12.1 CERTIFICATION I, Kal Sundaram, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mis |
|
| July 1, 2015 |
Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the ?Company?) on Form 20-F for the period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), we, Kal Sundaram, Chief Executive Officer an |
|
| July 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 27, 2015 |
a51110477.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Addres |
|
| May 19, 2015 |
a51106301.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant?s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Addres |
|
| February 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of princi |
|
| February 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2015 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of princi |
|
| December 24, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of princi |
|
| November 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| November 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of prin |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| August 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of princi |
|
| July 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principa |
|
| July 3, 2014 |
EX-13 Exhibit 13 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT 2002 In connection with the Annual Report of Taro Pharmaceutical Industries Ltd. (the “Company”) on Form 20-F for the period ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Kal Sundaram, Chief Executive Offi |
|
| July 3, 2014 |
EX-12.1 Exhibit 12.1 CERTIFICATION I, Kal Sundaram, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mis |
|
| July 3, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Form 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 3, 2014 |
EX-12.2 Exhibit 12.2 CERTIFICATION I, Michael Kalb, certify that: 1. I have reviewed this annual report on Form 20-F of Taro Pharmaceutical Industries Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not mis |
|
| May 27, 2014 |
Current Report of Foreign Issuer - TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of principal e |
|
| May 19, 2014 |
Current Report of Foreign Issuer - TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of principal e |
|
| March 27, 2014 |
Current Report of Foreign Issuer - TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of principal |
|
| March 7, 2014 |
Current Report of Foreign Issuer - PDF begin 644 positionstatement.pdf M)5!$1BTQ+C,*)9*@HHH*-"`P(&]B:@H\/"]4>7!E+UA/8FIE8W0*+U-U8G1Y M<&4O26UA9V4*+U=I9'1H(#$W,C@*+TAE:6=H="`R,C`P"B]":71S4&5R0V]M M<&]N96YT(#$*+T-O;&]R4W!A8V4O1&5V:6-E1W)A>0HO1FEL=&5R6R]#0TE4 M5$9A>$1E8V]D95T*+T1E8V]D95!A'3[IM4`!-GWW3[X^^^^^.H\W M3:H`";.O4)U"A0GW7>;[XZ]$(J39@`$V?Y0G7J%"=0G7*-\???,URM$TV!@` M)LR?==PG4*$^Z=0H4)T.A^Y4AV.8\]:;`H`";/ONH7*$^ZA.HW3*%RA#XH MGQTX' |
|
| March 7, 2014 |
Current Report of Foreign Issuer - TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of principal |
|
| February 19, 2014 |
Current Report of Foreign Issuer - TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2014 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant’s name into English) 14 Hakitor Street, Haifa Bay 26110, Israel (Address of princi |
